-
1
-
-
84872109456
-
The global prevalence of dementia: a systematic review and metaanalysis
-
23305823 e2
-
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63-75. e2.
-
(2013)
Alzheimers Dement
, vol.9
, pp. 63-75
-
-
Prince, M.1
Bryce, R.2
Albanese, E.3
Wimo, A.4
Ribeiro, W.5
Ferri, C.P.6
-
2
-
-
84872119357
-
Alzheimer Disease International. The worldwide economic impact of dementia 2010
-
23305821 e3
-
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9:1-11. e3.
-
(2013)
Alzheimers Dement
, vol.9
, pp. 1-11
-
-
Wimo, A.1
Jönsson, L.2
Bond, J.3
Prince, M.4
Winblad, B.5
-
3
-
-
43049129669
-
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations
-
1:CAS:528:DC%2BD1cXltFOkt7k%3D 18391487
-
Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord. 2008;25:408-22.
-
(2008)
Dement Geriatr Cogn Disord
, vol.25
, pp. 408-422
-
-
Farlow, M.R.1
Miller, M.L.2
Pejovic, V.3
-
4
-
-
84894122063
-
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
-
4086818 1:CAS:528:DC%2BC2cXjtVWrsL0%3D 24549548
-
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-91.
-
(2014)
JAMA
, vol.311
, pp. 682-691
-
-
Porsteinsson, A.P.1
Drye, L.T.2
Pollock, B.G.3
Devanand, D.P.4
Frangakis, C.5
Ismail, Z.6
-
5
-
-
78650210590
-
Immunotherapy for Alzheimer's disease
-
3074967 1:CAS:528:DC%2BC3MXhsFKms7s%3D 21158978
-
Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med. 2011;269:54-63.
-
(2011)
J Intern Med
, vol.269
, pp. 54-63
-
-
Morgan, D.1
-
6
-
-
0034700471
-
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
-
1:CAS:528:DC%2BD3MXhslWitg%3D%3D 11140685
-
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-82.
-
(2000)
Nature
, vol.408
, pp. 979-982
-
-
Janus, C.1
Pearson, J.2
McLaurin, J.3
Mathews, P.M.4
Jiang, Y.5
Schmidt, S.D.6
-
7
-
-
70049083865
-
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
-
1:CAS:528:DC%2BD1MXhtFGktLzF 18294736
-
Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728-36.
-
(2009)
Neurobiol Aging
, vol.30
, pp. 1728-1736
-
-
Relkin, N.R.1
Szabo, P.2
Adamiak, B.3
Burgut, T.4
Monthe, C.5
Lent, R.W.6
-
8
-
-
4644275963
-
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
-
1738770 1:STN:280:DC%2BD2cvpvFyqsA%3D%3D 15377700
-
Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:1472-4.
-
(2004)
J Neurol Neurosurg Psychiatry
, vol.75
, pp. 1472-1474
-
-
Dodel, R.C.1
Du, Y.2
Depboylu, C.3
Hampel, H.4
Frölich, L.5
Haag, A.6
-
9
-
-
0033536163
-
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
-
1:CAS:528:DyaK1MXks1Khsbc%3D 10408445
-
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-7.
-
(1999)
Nature
, vol.400
, pp. 173-177
-
-
Schenk, D.1
Barbour, R.2
Dunn, W.3
Gordon, G.4
Grajeda, H.5
Guido, T.6
-
10
-
-
48949085739
-
Amyloid-β immunisation for Alzheimer's disease
-
2752661 1:CAS:528:DC%2BD1cXhtFWmsLrJ 18667360
-
Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol. 2008;7:805-11.
-
(2008)
Lancet Neurol
, vol.7
, pp. 805-811
-
-
Wisniewski, T.1
Konietzko, U.2
-
11
-
-
79959670013
-
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
-
1:CAS:528:DC%2BC3MXos1yisrs%3D 21697382
-
Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31:9323-31.
-
(2011)
J Neurosci
, vol.31
, pp. 9323-9331
-
-
Wiessner, C.1
Wiederhold, K.H.2
Tissot, A.C.3
Frey, P.4
Danner, S.5
Jacobson, L.H.6
-
12
-
-
0033835996
-
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
-
1:CAS:528:DC%2BD3cXlsFamtL4%3D 10932230
-
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-9.
-
(2000)
Nat Med
, vol.6
, pp. 916-919
-
-
Bard, F.1
Cannon, C.2
Barbour, R.3
Burke, R.L.4
Games, D.5
Grajeda, H.6
-
13
-
-
84896691913
-
Pathways to Alzheimer's disease
-
1:CAS:528:DC%2BC2cXkt12iu78%3D 24749173
-
Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, et al. Pathways to Alzheimer's disease. J Intern Med. 2014;275:296-303.
-
(2014)
J Intern Med
, vol.275
, pp. 296-303
-
-
Hardy, J.1
Bogdanovic, N.2
Winblad, B.3
Portelius, E.4
Andreasen, N.5
Cedazo-Minguez, A.6
-
14
-
-
84892748542
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
-
1:CAS:528:DC%2BC2cXhs1Ggt70%3D 24450890
-
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
-
(2014)
N Engl J Med
, vol.370
, pp. 311-321
-
-
Doody, R.S.1
Thomas, R.G.2
Farlow, M.3
Iwatsubo, T.4
Vellas, B.5
Joffe, S.6
-
15
-
-
84892695519
-
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
-
4159618 1:CAS:528:DC%2BC2cXhs1Ggt7o%3D 24450891
-
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
-
(2014)
N Engl J Med
, vol.370
, pp. 322-333
-
-
Salloway, S.1
Sperling, R.2
Fox, N.C.3
Blennow, K.4
Klunk, W.5
Raskind, M.6
-
16
-
-
10744230547
-
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
-
1:CAS:528:DC%2BD3sXks1OktLk%3D 12847155
-
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61:46-54.
-
(2003)
Neurology
, vol.61
, pp. 46-54
-
-
Orgogozo, J.M.1
Gilman, S.2
Dartigues, J.F.3
Laurent, B.4
Puel, M.5
Kirby, L.C.6
-
17
-
-
84862331908
-
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
-
1:CAS:528:DC%2BC38XovVygsr0%3D 22677258
-
Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11:597-604.
-
(2012)
Lancet Neurol
, vol.11
, pp. 597-604
-
-
Winblad, B.1
Andreasen, N.2
Minthon, L.3
Floesser, A.4
Imbert, G.5
Dumortier, T.6
-
18
-
-
84862777153
-
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
-
4063417 1:CAS:528:DC%2BC38XislSqs74%3D 22305802
-
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241-9.
-
(2012)
Lancet Neurol
, vol.11
, pp. 241-249
-
-
Sperling, R.1
Salloway, S.2
Brooks, D.J.3
Tampieri, D.4
Barakos, J.5
Fox, N.C.6
-
20
-
-
0021271971
-
Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA work group under the auspices of Department Of Health And Human Services Task Force on Alzheimer's disease
-
1:STN:280:DyaL2c3ks1altQ%3D%3D 6610841
-
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA work group under the auspices of Department Of Health And Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-44.
-
(1984)
Neurology
, vol.34
, pp. 939-944
-
-
McKhann, G.1
Drachman, D.2
Folstein, M.3
Katzman, R.4
Price, D.5
Stadlan, E.M.6
-
21
-
-
84903309463
-
Stability of anti-immunotherapeutic antibodies in frozen human serum samples
-
1:CAS:528:DC%2BC2cXhtVenu7nE 24958123
-
Michaut L, Laurent N, Kentsch K, Spindeldreher S, Deckert-Salva F. Stability of anti-immunotherapeutic antibodies in frozen human serum samples. Bioanalysis. 2014;6:1395-407.
-
(2014)
Bioanalysis
, vol.6
, pp. 1395-1407
-
-
Michaut, L.1
Laurent, N.2
Kentsch, K.3
Spindeldreher, S.4
Deckert-Salva, F.5
-
22
-
-
0141751616
-
Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study
-
14550701
-
Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet. 2003;362:1121-2.
-
(2003)
Lancet
, vol.362
, pp. 1121-1122
-
-
Chan, D.1
Janssen, J.C.2
Whitwell, J.L.3
Watt, H.C.4
Jenkins, R.5
Frost, C.6
-
23
-
-
2542502430
-
ApoE genotype accounts for the vast majority of AD risk and AD pathology
-
1:CAS:528:DC%2BD2cXksVGgtLw%3D 15172743
-
Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641-50.
-
(2004)
Neurobiol Aging
, vol.25
, pp. 641-650
-
-
Raber, J.1
Huang, Y.2
Ashford, J.W.3
-
24
-
-
0027503277
-
Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age
-
1:STN:280:DyaK3s3itlOhsg%3D%3D 8467819
-
Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Långström G, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol. 1993;33:129-33.
-
(1993)
Eur Neurol
, vol.33
, pp. 129-133
-
-
Blennow, K.1
Fredman, P.2
Wallin, A.3
Gottfries, C.G.4
Karlsson, I.5
Långström, G.6
-
25
-
-
84895729926
-
Amyloid-β-directed immunotherapy for Alzheimer's disease
-
4238820 1:CAS:528:DC%2BC2cXkt12iu7w%3D 24605809
-
Lannfelt L, Relkin NR, Siemers ER. Amyloid-β-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284-95.
-
(2014)
J Intern Med
, vol.275
, pp. 284-295
-
-
Lannfelt, L.1
Relkin, N.R.2
Siemers, E.R.3
-
26
-
-
72149123967
-
Total and phosphorylated tau protein as biological markers of Alzheimer's disease
-
2815003 1:CAS:528:DC%2BD1MXhsFynt7nN 19853650
-
Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. 2010;45:30-40.
-
(2010)
Exp Gerontol
, vol.45
, pp. 30-40
-
-
Hampel, H.1
Blennow, K.2
Shaw, L.M.3
Hoessler, Y.C.4
Zetterberg, H.5
Trojanowski, J.Q.6
-
27
-
-
80052846251
-
Longitudinal changes of CSF biomarkers in Alzheimer's disease
-
21460434
-
Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis. 2011;25:583-94.
-
(2011)
J Alzheimers Dis
, vol.25
, pp. 583-594
-
-
Seppälä, T.T.1
Koivisto, A.M.2
Hartikainen, P.3
Helisalmi, S.4
Soininen, H.5
Herukka, S.K.6
-
28
-
-
84897505354
-
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease
-
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Science Transl Med. 2014;6:226ra230.
-
(2014)
Science Transl Med
, vol.6
, pp. 226ra230
-
-
Fagan, A.M.1
Xiong, C.2
Jasielec, M.S.3
Bateman, R.J.4
Goate, A.M.5
Benzinger, T.L.6
-
29
-
-
47149112621
-
42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
-
1:CAS:528:DC%2BD1cXoslWkt74%3D 18640458
-
42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-23.
-
(2008)
Lancet
, vol.372
, pp. 216-223
-
-
Holmes, C.1
Boche, D.2
Wilkinson, D.3
Yadegarfar, G.4
Hopkins, V.5
Bayer, A.6
-
30
-
-
84876209795
-
Brain β-amyloid load approaches a plateau
-
3653215 1:CAS:528:DC%2BC3sXjsFOitLw%3D 23446680
-
Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain β-amyloid load approaches a plateau. Neurology. 2013;80:890-6.
-
(2013)
Neurology
, vol.80
, pp. 890-896
-
-
Jack, C.R.1
Wiste, H.J.2
Lesnick, T.G.3
Weigand, S.D.4
Knopman, D.S.5
Vemuri, P.6
-
31
-
-
77950805621
-
Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Rev Neurol. 2010;6:108-19. A published erratum appears in Nat
-
Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Rev Neurol. 2010;6:108-19. A published erratum appears in Nat. Rev Neurol. 2010;6:183.
-
(2010)
Rev Neurol
, vol.6
, pp. 183
-
-
Lemere, C.A.1
Masliah, E.2
-
32
-
-
84895729886
-
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
-
3956752 1:STN:280:DC%2BC2crhsFaqug%3D%3D 24605808
-
Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251-83.
-
(2014)
J Intern Med
, vol.275
, pp. 251-283
-
-
Schneider, L.S.1
Mangialasche, F.2
Andreasen, N.3
Feldman, H.4
Giacobini, E.5
Jones, R.6
|